Document is current
Any future updates will be listed below
-
Authors
Yoshichika, Ryo
Mukohara, Fumiaki
Yamada, Kotaro
Nagasaki, Joji
Watanabe, Hiroko
Ueda, Youki
Suzawa, Ken
Shien, Kazuhiko
Toyooka, Shinichi
Ishino, Takamasa
Togashi, Yosuke
-
Funding
Funding for this research was provided by:
Janssen Pharmaceutical K.K.
Okayama University
- License Information
-
More Information
Article History
Received: 18 November 2025
Accepted: 16 March 2026
First Online: 24 March 2026
Declarations
:
: S. Toyooka received research grants from TAIHO PHARMA, Eli Lilly, Chugai Pharmaceutical and Astellas Pharma, and honoraria from TAIHO PHARMA, Eli Lilly, Chugai Pharmaceutical, GUARDANT, AstraZeneca, Illumina, MERCK, CSL Behring, Nippon Kayaku, Daiichi-Sankyo, Ono Pharmaceutical, Medtronic, Ziosoft, NOVARTIS, Sysmex and Riken Genesis outside of this study. Y. Togashi received a research grant from Janssen Pharmaceutical K.K. for this study. Y. Togashi received research grants from AstraZeneca, TAIHO PHARMA, Takeda, Chugai Pharmaceutical, Daiichi-Sankyo, and KORTUC, and honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, AstraZeneca, Chugai Pharmaceutical, Eisai and MSD outside of this study. The other authors declare that they have no research support relevant to financial competing interests.
: All patients provided written informed consent.
: All patients provided written informed consent. Ethical Approval. The study protocol was approved by the Institutional Review Board of Okayama University.
